Cargando…

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis

OBJECTIVE: To compare the safety and efficacy of switching from reference adalimumab to adalimumab biosimilar CT-P17 with continuing reference adalimumab/CT-P17 in active RA. METHODS: This double-blind, phase III study randomized (1:1) subjects with active RA to receive 40 mg (100 mg/ml) CT-P17 or E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furst, Daniel E, Jaworski, Janusz, Wojciechowski, Rafal, Wiland, Piotr, Dudek, Anna, Krogulec, Marek, Jeka, Slawomir, Zielinska, Agnieszka, Trefler, Jakub, Bartnicka-Maslowska, Katarzyna, Krajewska-Wlodarczyk, Magdalena, Klimiuk, Piotr A, Lee, Sang Joon, Kim, Sung Hyun, Bae, Yun Ju, Yang, Go Eun, Yoo, Jae Kyoung, Kay, Jonathan, Keystone, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996790/ https://www.ncbi.nlm.nih.gov/pubmed/34142111 http://dx.doi.org/10.1093/rheumatology/keab460

Ejemplares similares

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
por: Kay, Jonathan, et al.
Publicado: (2021)

Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT‐P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects
por: Davidson, Antonia, et al.
Publicado: (2021)

Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis
por: Iwaszko, Milena, et al.
Publicado: (2018)

Addendum: Iwaszko et al., Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. Genes 2018, 9, 64
por: Iwaszko, Milena, et al.
Publicado: (2018)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects
por: Yu, Kyung‐Sang, et al.
Publicado: (2021)

Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology
por: Kucharz, Eugeniusz J., et al.
Publicado: (2018)

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
por: Keystone, Edward C, et al.
Publicado: (2018)

Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis
por: Iwaszko, Milena, et al.
Publicado: (2020)

Monostotic Paget’s disease of bone – literature review and case report
por: Wysiński, Piotr, et al.
Publicado: (2019)

Baseline new bone formation does not predict bone loss in ankylosing spondylitis as assessed by quantitative computed tomography (QCT) - 10-year follow-up
por: Korkosz, Mariusz, et al.
Publicado: (2011)

The role of ultrasonography in monitoring long-standing rheumatoid arthritis: a pilot study
por: Jeka, Sławomir, et al.
Publicado: (2017)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Unusual location of tuberculosis in the course of tumor necrosis factor α inhibitor therapy
por: Bielewicz-Zielińska, Agnieszka, et al.
Publicado: (2015)

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
por: Cohen, Stanley B, et al.
Publicado: (2018)

Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial
por: Suh, Chang-Hee, et al.
Publicado: (2019)

Mini-laparascopic dismembered pyeloplasty using only 3 mm instruments (3 mmML)
por: Jarzemski, Piotr, et al.
Publicado: (2015)

Assessment of the usefulness of skin autofluorescence as an indicator of disease activity and of the risk of developing diabetes in patients suffering from rheumatoid arthritis
por: Jeka, Sławomir, et al.
Publicado: (2015)

Editorial Comment on I. Sudoł-Szopińska, E. Kontny, W. Maśliński, M. Prochorec-Sobieszek, B. Kwiatkowska, K. Zaniewicz-Kaniewska, A. Warczyńska The pathogenesis of rheumatoid arthritis in radiological studies. Part I: Formation of inflammatory infiltrates within the synovial membrane and I. Sudoł-Szopińska, K. Zaniewicz-Kaniewska, A. Warczyńska, G. Matuszewska, F. Saied, W. Kunisz The pathogenesis of rheumatoid arthritis in radiological studies. Part II: Imaging studies in rheumatoid arthritis
por: Wiland, Piotr
Publicado: (2012)

Panta rhei in diagnosing rheumatic diseases
por: Wiland, Piotr
Publicado: (2019)

Diagnosis and management of gastrointestinal chemical burns and post-burn oesophageal stenosis
por: Obarski, Piotr, et al.
Publicado: (2022)

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Atypical course of Henoch-Schonlein purpura in an adult patient
por: Bielewicz-Zielińska, Agnieszka, et al.
Publicado: (2015)

Pleural Effusion in Meigs’ Syndrome—Transudate or Exudate?: Systematic Review of the Literature
por: Krenke, Rafal, et al.
Publicado: (2015)

Factors associated with quality of life in systemic sclerosis: a cross-sectional study
por: Sierakowska, Matylda, et al.
Publicado: (2019)

Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial
por: Elewski, B.E., et al.
Publicado: (2019)

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study
por: Wiland, Piotr, et al.
Publicado: (2020)

Brainstem auditory evoked potentials in patients with primary Sjögren’s syndrome without central nervous system involvement
por: Waliszewska-Prosół, Marta, et al.
Publicado: (2020)

Antibodies to Citrullinated Proteins (ACPA) Associate with Markers of Osteoclast Activation and Bone Destruction in the Bone Marrow of Patients with Rheumatoid Arthritis
por: Kurowska, Weronika, et al.
Publicado: (2021)

Assessment of the Microbiological Quality of Ready-to-Eat Salads—Are There Any Reasons for Concern about Public Health?
por: Łepecka, Anna, et al.
Publicado: (2022)

Surgical treatment of thoracic esophageal diverticula
por: Wlodarczyk, Janusz, et al.
Publicado: (2023)

People of the 21(st) century: Where we came from – Who we are – Where we are going
por: Oleś, Piotr K., et al.
Publicado: (2021)

Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study
por: Haraoui, Boulos, et al.
Publicado: (2011)

Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52‐week phase 3 open‐label study
por: Yamasaki, Kenshi, et al.
Publicado: (2022)

Polish Medical Society of Radiology and Polish Society of Rheumatology Recommendations for Magnetic Resonance Imaging of Musculoskeletal Disorders in Rheumatology
por: Sudoł-Szopińska, Iwona, et al.
Publicado: (2015)

Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis
por: Nash, Peter, et al.
Publicado: (2016)

Graphene Oxide Decreases Pro-Inflammatory Proteins Production in Skeletal Muscle Cells Exposed to SARS-CoV-2 Spike Protein
por: Bałaban, Jaśmina, et al.
Publicado: (2023)

Cloning, Expression and Characterization of a Novel Cold-adapted β-galactosidase from the Deep-sea Bacterium Alteromonas sp. ML52
por: Sun, Jingjing, et al.
Publicado: (2018)

High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage
por: Korkosz, Mariusz, et al.
Publicado: (2013)

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
por: Keystone, Edward C, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ambqio391l3rl24fjdfngsk7ak